Description
ADCC-Enhanced anti-IRTA4 (9G11) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
B-cell malignancies
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IRTA4 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
FCRL2
Full Name
Fc receptor-like 2
Background
This gene encodes a member of the immunoglobulin receptor superfamily and is one of several Fc receptor-like glycoproteins clustered on the long arm of chromosome 1. The encoded protein has four extracellular C2-type immunoglobulin domains, a transmembrane domain and a cytoplasmic domain that contains one immunoreceptor-tyrosine activation motif and two immunoreceptor-tyrosine inhibitory motifs. This protein may be a prognostic marker for chronic lymphocytic leukemia. Alternatively spliced transcript variants have been described, but their biological validity has not been determined.
Alternative Names
FCRL2; Fc receptor-like 2; FCRH2; IFGP4; IRTA4; SPAP1; CD307b; SPAP1A; SPAP1B; SPAP1C; Fc receptor-like protein 2; IFGP family protein 4; fc receptor homolog 2; immunoglobulin superfamily Fc receptor, gp42; SH2 domain containing phosphatase anchor protein 1; immune receptor translocation-associated protein 4; immunoglobulin receptor translocation-associated protein 4
Gene ID
79368
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with FCRL2 include Spastic Paraplegia 62, Autosomal Recessive.
Function
May have an regulatory role in normal and neoplastic B cell development.
Post-translational modifications
1.Isoform 2 is N- and O-glycosylated, and phosphorylated 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn343, Asn355, Asn365, Asn204, and Asn234
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
9G11
Description
The monoclonal antibody that specifically bind to IRTA-4 with high affinity can be used for treating various B cell malignancies, including non-Hodgkin's lymphoma.
Antibody Indication
B-cell malignancies
